• Home
  • Sitemap
  • Help
  • Technical Support
  • Contact
Toolbar - View Selection
 
Items 1 of 1
ALX-805-046 Revised 21-Feb-07
Monoclonal Antibody to CD40 (mouse) (FGK45)
Add to Clipboard
SYNONYMS anti-TNFRSF 5 (mouse) MAb (FGK45)
PRODUCT LINE Chemokines & Cytokines
PRODUCT CATEGORY CD40 & CD40L [CD154] / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-805-046B-C050 Biotin 50 µg 150.00 USD Add To Cart
ALX-805-046-C100   100 µg 165.00 USD Add To Cart
ALX-805-046-C500   500 µg 440.00 USD Add To Cart
Product Specification
SPECIES CROSSREACTIVITY:
Mouse
CLONE: FGK45
ISOTYPE: Rat IgG2a
CONCENTRATION: FGK45: 1mg/ml
FGK45-Biotin: 0.5mg/ml
PURITY DETAIL: Protein G-affinity purified.
FORMULATION: Liquid. In sterile PBS.
IMMUNOGEN: Recombinant mouse CD40 fusion protein.
SPECIFICITY: Recognizes mouse CD40.
APPLICATION: Flow Cytometry
Functional Application (activates B and NK cells in vivo and in vitro)
SHIPPING: SHIPPED ON BLUE ICE
SHORT TERM STORAGE: +4°C
USE/STABILITY:

For long term storage keep unconjugated antibody at -20°C. Avoid freeze/thaw cycles. Keep Biotin-conjugated formats at +4°C. Do not freeze. Protect from light.

Product Images
Please click on thumbnails to enlarge.
Product Description
Widely used stimulatory MAb to CD40 [1,2]. Shown to indirectly activate natural killer (NK) cells, producing significant antitumor and antimetastatic effects [3]. Effective in boosting immune responses against infectious agents and can potentially be used to treat chronic autoimmune inflammatory processes [4]. 
Product Specific Literature References
[1] The SCID but not the RAG-2 gene product is required for S mu-S epsilon heavy chain class switching: A. Rolink, et al.; Immunity 5, 319 (1996) Abstract
[2] Characterization of immature B cells by a novel monoclonal antibody, by turnover and by mitogen reactivity: A.G. Rolink, et al.; Eur. J. Immunol. 28, 3738 (1998) Abstract
[3] Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells: J.G. Turner, et al.; J. Immunol. 166, 89 (2001) Abstract
[4] Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process: C. Mauri, et al.; Nat. Med. 6, 673 (2000) Abstract
Click here for a complete literature overview:
[40] Ovarian insufficiency and early pregnancy loss induced by activation of the innate immune system: A. Erlebacher, et al.; J. Clin. Invest. 114, 39 (2004) Abstract; Full Text
[41] CD154 is a negative regulator of autoaggressive CD8+ T cells in type 1 diabetes: C.M. McGregor, et al.; PNAS 101, 9345 (2004) Abstract; Full Text
[42] IRF-7 is the master regulator of type-I interferon-dependent immune responses: K. Honda, et al.; Nature 434, 772 (2005) Abstract
[43] In vivo and in vitro regulation of type I IFN synthesis by synergistic effects of CD40 and type II IFN: J.A. Greene, et al.; J. Immunol. 176, 5995 (2006) Abstract
[44] IL-10- and IL-12-independent down-regulation of allergic sensitization by stimulation of CD40 signaling: P.W. Hellings, et al.; J. Immunol. 177, 5138 (2006) Abstract
[45] Agonistic Anti-CD40 Antibody Profoundly Suppresses the Immune Response to Infection with Lymphocytic Choriomeningitis Virus: C. Bartholdy, et al.; J. Immunol. 178, 1662 (2007) Abstract
Further Categories Containing This Product:
CD AntibodiesMonoclonal Antibodies
 
 

Your items will be kept only for the duration of your visit.